Tetraphase will report data from a phase III study of eravacycline in which the experimental antibiotic is first given by intravenous infusion and then transitioned to an oral form.
Epizyme's technology platform focuses on developing drugs to regulate a class of cancer-causing enzymes.
Imbruvica will be an important part of the treatment landscape for blood cancers.
If biotech companies can assuage concerns about long-term growth, multiples might expand.
The Seattle Genetics' bull thesis will be tested when results are announced from the "AETHERA" study of Adcetris in post-stem cell transplant Hodgkin's lymphoma patients.
The year is halfway over, so it's a good time to look back and give mid-term grades on my fearless 2014 predictions.
Is a slowdown in Sovaldi prescriptions the beginning of the highly anticipated "re-warehousing" of patients, or is some other factor at play?
Treating pancreatic cancer patients with Jakafi might have a minor benefit, but the totality of the results in the phase II trial do not inspire high confidence in the phase III program.
Foundation Medicine released the results of its decision analytics study earlier Saturday morning at the American Society of Clinical Oncology annual meeting, demonstrating 27.3% of doctors altered their prescriptions based on a FoundationOne diagnostic test.
Foundation Medicine has a comparative advantage over other diagnostic companies which investors are failing to recognize.